Octapharma

Quick facts

Marketed products

• Antithrombin III · Cardiovascular; Hematology
  Antithrombin III is a natural anticoagulant protein that inhibits blood clotting factors (thrombin and factor Xa) to prevent pathological thrombosis.
• Atenativ · Other
• Balfaxar · Other
• Gammanorm · Other
• Panzyga · Other

Phase 3 pipeline

• Human cl rhFVIII · Hematology
  Human cl rhFVIII is a recombinant human Factor VIII that replaces deficient or dysfunctional clotting factor VIII to restore blood coagulation in hemophilia A patients.
• Human plasma derived antithrombin · Cardiovascular; Hematology
  Antithrombin is a natural anticoagulant protein that inhibits blood clotting factors to prevent thrombosis.
• human VWF/FVIII concentrate · Hematology
  Human VWF/FVIII concentrate replaces clotting factors in the blood to prevent or control bleeding episodes in patients with hemophilia A.
• NewGam · Immunology
  Provides passive immunity and immune modulation through polyspecific human immunoglobulins that interact with Fc receptors and complement components.
• Newnorm · Other
• OCTA-C1-INH · Immunology / Rare Disease
  OCTA-C1-INH is a recombinant C1-esterase inhibitor that replaces or augments deficient or dysfunctional C1-inhibitor protein to prevent excessive complement and contact system activation.
• Octafibrin · Other
• octanorm 16.5% · Critical Care / Hematology
  Octanorm 16.5% is a human albumin solution that restores intravascular oncotic pressure and maintains plasma volume in patients with hypoproteinemia or acute blood loss.
• Octaplex · Other
• Panzyga, 10% Intravenous Solution · Immunology
  Panzyga is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and reduce inflammation.
• recombinant Factor VIII
  Replaces deficient or absent Factor VIII protein to restore normal blood coagulation cascade function in hemophilia A patients.

Phase 2 pipeline

• Eqwilate · Other
• Haemocomplettan® P or RiaSTAPTM
• Kogenate FS
• Octagam 5%
• Octagam IVIG 5% or 10%
• Octaplas LG
• Other marketed IVIG product
• Other Subcutaneous Immunoglobulins
• Von Willebrand Factor-Containing Product

Phase 1 pipeline

• Octaplas SD

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Octapharma portfolio CI brief
• Octapharma pipeline updates RSS

Frequently asked questions about Octapharma

Related

• Antithrombin III · Cardiovascular; Hematology
• Atenativ · Other
• Balfaxar · Other
• Gammanorm · Other
• Panzyga · Other
• Sector hub: All tracked pharma companies